Table 1.
Guidelines for Antiobesity Treatments
| BMI╲ Intervention | Lifestyle | Anti-obesity medications | Sleeve Gastroplasty | Bariatric Surgery |
|---|---|---|---|---|
| 25–26.9 | Yes | |||
| 27–29.9 | Yes | Yes, with adiposity-related comorbiditiesa | Yes, with adiposity-related comorbiditiesa | |
| 30–34.9 | Yes | Yes | Yes | Yes, with metabolic syndrome |
| 35–39.9 | Yes | Yes | Yes | Yes, with adiposity-related comorbiditiesa |
| >40 | Yes | Yes | Yes | Yes |
| Estimated weight loss at 1 year (%)[135] | 5–7% | 5–15% | 15–17% | 25–30% |
a
Indicated if adiposity-related comorbidities are present. These include type 2 diabetes, hypertension, dyslipidemia, cardiovascular disease, obstructive sleep apnea, gastroesophageal acid reflux, osteoarthritis, among others.